Bay Colony Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Bay Colony Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2	Closed	–	–	396
2018 Q2	$0	Buy	+2	New	+$200	﹤0.01%	937

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Bay Colony Advisors's ENTA Position: Q3 2018 in Review

Bay Colony Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2018, closing a stake of 2 shares.

Bay Colony Advisors first reported a position in ENTA in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 197 funds tracked by Wall St. Rank hold ENTA as of Q3 2018.

Bay Colony Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bay Colony Advisors sold 2 Enanta Pharmaceuticals shares in Q3 2018.
Bay Colony Advisors first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Bay Colony Advisors's Enanta Pharmaceuticals position peaked at $0 in Q2 2018.
197 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2018.

Based on Bay Colony Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.